Braeu, N., Wyles, D., Kottilil, S., Darr, E., Workowski, K., Luetkemeyer, A., … Sulkowski, M. (2016). Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 19). JOHN WILEY & SONS LTD.

Braeu, N., D. Wyles, S. Kottilil, E. Darr, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, Vol. 19. JOHN WILEY & SONS LTD, 2016.

Braeu N, Wyles D, Kottilil S, Darr E, Workowski K, Luetkemeyer A, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. JOHN WILEY & SONS LTD; 2016.

Braeu, N., et al. “Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 19, JOHN WILEY & SONS LTD, 2016.

Braeu N, Wyles D, Kottilil S, Darr E, Workowski K, Luetkemeyer A, Adeyemi O, Ruane P, Doehle B, Huang KC, Osinusi A, McNally J, Natha M, Guion M, McLean T, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. JOHN WILEY & SONS LTD; 2016.